Advertisement

OMAS editorial

Published:November 04, 2022DOI:https://doi.org/10.1016/j.ejpn.2022.11.001
      Yildirim et al. present the clinical phenotype and outcomes of 23 children presenting to two Children's hospitals in Turkey over an eleven-year period [
      • Yıldırım M.
      • Öncel İ.
      • Bektaş Ö.
      • et al.
      Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Paediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yıldırım M.
        • Öncel İ.
        • Bektaş Ö.
        • et al.
        Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome.
        Eur. J. Paediatr. Neurol. 2022; 41 (0): 19-26https://doi.org/10.1016/j.ejpn.2022.09.002
        • de Alarcon P.A.
        • Matthay K.K.
        • London W.B.
        • et al.
        Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
        Lancet Child Adolesc Heal. 2018; 2: 25-34https://doi.org/10.1016/S2352-4642(17)30130-X
        • De Grandis E.
        • Parodi S.
        • Conte M.
        • et al.
        Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome.
        Neuropediatrics. 2009; 40: 103-111https://doi.org/10.1055/s-0029-1237723
        • Rossor T.
        • Yeh E.A.
        • Khakoo Y.
        • et al.
        Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children.
        Neurol - Neuroimmunol Neuroinflammation. 2022; 9https://doi.org/10.1212/NXI.0000000000001153